Core Viewpoint - Hong Kong Exchanges and Clearing Limited (HKEX) has launched the Hang Seng Tech 100 Index, the first index for Hong Kong stocks, which tracks the performance of the largest 100 technology companies listed on the Hong Kong Stock Exchange [1] Group 1: Index Composition and Criteria - The Hang Seng Tech 100 Index includes companies that meet specific liquidity and growth criteria: a minimum average daily trading volume of HKD 20 million over the past six months and either R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Selected companies include major players such as Tencent Holdings, Alibaba Group, BYD Company, and Xiaomi Group, among others [1] - The index covers six innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] Group 2: Index Methodology and Adjustments - The index uses a free-float market capitalization weighting method, with a cap of 12% on the weight of any single constituent [1] - Constituents are reviewed and adjusted biannually, with data cut-off dates at the end of April and October each year [1] Group 3: Liquidity and Fundamental Requirements - The index has strict liquidity and fundamental requirements: securities with an average daily trading amount below HKD 20 million or ranking in the bottom 10% by trading volume will be excluded [2] - Companies with R&D spending below 3% of revenue or revenue growth below 5% over the past two fiscal years will also be excluded, although companies listed under Chapter 18A or 18C may be exempt from these fundamental requirements [2] - This design aims to select technology stocks with market interest and growth potential, facilitating the development of related products in the mainland Chinese market and meeting the demand for technology investments from mainland investors [2]

进入12月，药明康德迎来了成立的第25个年头。四分之一世纪的时光，这家CXO企业从上海一间650平 方米的实验室，成长为在亚洲、欧洲、北美拥有超过20个研发生产基地、服务全球数千家客户的一体化 CRDMO赋能平台。在这段发展历程中，药明康德用实践诠释了何谓穿越周期的"长期主义"。 一体化CRDMO模式打通增长通路 药明康德得以在多个经济与行业周期中持续增长，核心驱动力正是其长期坚持的"一体化，端到 端"CRDMO业务模式。这一模式实现了药物发现与研究(R)、工艺开发(D)和商业化生产(M)的无缝贯 通，通过内部高效协同形成增长飞轮。 例如，药明康德在靶向蛋白降解(TPD)领域的发展，正是其CRDMO模式优势的重要体现。早在科学转 化的初期，药明康德就从R端捕捉到创新趋势，于近10年前开始布局相关能力和技术，并跟随前沿科学 陆续构建了涵盖多种分子类型的技术平台。另一方面，R端对下游D&M端业务起到引流作用。如今， 已有超过18.8万种复杂的TPD化合物从药明康德的赋能平台走出，其中70多种已进入临床前候选药物阶 段，10多种已进入后期开发阶段。 在下游，D&M端的规模化、一体化能力，实现技术的快速放大与高效产出 ...

Group 1 - The core viewpoint of the news highlights the significant increase in the success rate of national medical insurance negotiations, reaching a historical high, which is expected to encourage the development of innovative drugs in China [2] - The 2025 National Medical Insurance Drug List will add 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, marking a notable increase from 76% in 2024 [1] - The new drug list will officially implement on January 1, 2026, expanding the total number of drugs covered to 3,253, enhancing coverage in key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2 - Citic Securities believes that the successful negotiation rate for national medical insurance has reached a historical high, and the commercial insurance directory is expected to become an important growth driver, promoting the development of innovative drugs [2] - Guotai Junan Securities indicates that the recent press conference and series of discussions by the medical insurance bureau clarify future policies that support companies in "anti-involution," international expansion, and differentiated innovation, which will benefit the high-quality development of the medical device industry [2] - The China Innovation Drug ETF closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

Core Viewpoint - The pharmaceutical and biotechnology sector has demonstrated resilience and growth potential in 2023, driven by policy support and industry transformation, leading to a high-quality development phase characterized by innovation and cost control [1][4]. Industry Performance - As of December 8, 2023, the pharmaceutical and biotechnology sector has shown a weighted average increase of 30.64% in market capitalization, ranking 14th among 31 primary industries, but underperforming the CSI 300 index by 3.82 percentage points [2]. - The sector has exhibited significant internal differentiation, with innovation-driven segments outperforming others; for instance, other biological products, chemical preparations, and medical R&D outsourcing saw increases of 57.07%, 54.68%, and 51.87% respectively, while traditional Chinese medicine, vaccines, and blood products lagged with increases of only 3.89%, -0.73%, and -10.85% [2]. Factors Influencing Growth - The strong performance of the innovative drug industry chain is attributed to four key factors: exceeding expectations in earnings from leading companies like BeiGene and WuXi AppTec, ongoing supportive policies for innovative drugs and devices, increased activity in domestic innovative drug business development (BD) transactions, and substantial clinical data disclosures at major global conferences [2]. Recent Adjustments - Since September 2023, the sector has experienced a pullback due to prior significant gains, unmet expectations in some BD transactions, and geopolitical disturbances, with a maximum drawdown of 12.72% from September 1 to November 21 [3]. Valuation Insights - As of December 8, 2023, the sector's price-to-earnings (P/E) ratio stands at 51.75, ranking 10th among primary industries, with a premium of 267.54% over the CSI 300 index and 63.87% over all A-shares (excluding banks), indicating a relatively high valuation level historically [3]. Policy Impact - The policy environment has significantly upgraded support for the pharmaceutical and biotechnology industry, with the "14th Five-Year Plan" emphasizing the development of innovative drugs and medical devices, and the "15th Five-Year Plan" extending support to the entire value chain [6]. - The focus on key technological breakthroughs in areas such as dual antibodies, ADCs, and mRNA is expected to drive further differentiation within the industry [6]. Investment Opportunities - Three main investment themes are highlighted: 1. The innovative drug sector, which is expected to thrive due to policy support and strong performance from leading companies [7]. 2. The CXO sector, benefiting from increased demand for innovative drug development and showing significant performance improvements [7]. 3. Consumer healthcare companies, which are anticipated to recover as consumer demand increases, presenting dual potential for valuation recovery and earnings growth [7]. Technological Integration - The integration of AI technologies into the biopharmaceutical industry is expected to enhance research efficiency and product development, with AI applications improving diagnostic processes and overall healthcare delivery [8].

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Investment Rating - The report indicates a slight decrease in the overall investment rating for the pharmaceutical sector, with public fund holdings at 9.67%, down by 0.21 percentage points from the previous quarter [2][9]. Core Insights - The pharmaceutical sector's market capitalization accounted for 7.83% of the total market, reflecting an increase of 1.52 percentage points [2][9]. - The top five holdings by public funds include 恒瑞医药 (Hengrui Medicine) with 745 funds, 药明康德 (WuXi AppTec) with 608 funds, 信达生物 (Innovent Biologics) with 297 funds, 迈瑞医疗 (Mindray) with 249 funds, and 三生制药 (3SBio) with 206 funds [2][9]. - The report highlights a significant increase in foreign investment, with a total market value of 1839.40 billion yuan, up by 229.2 billion yuan from the beginning of the period [6][10]. Summary by Sections Public Fund Holdings - The total public fund holdings in the pharmaceutical sector decreased to 9.67%, with a notable drop in active pharmaceutical fund holdings to 6.74% [2][9]. - The market capitalization of the pharmaceutical sector increased to 76270.93 billion yuan [13]. Sector Performance - The top sectors by public fund holdings include chemical preparations at 28.75%, other biological products at 14.27%, and medical research outsourcing at 9.16% [19][20]. - The report notes a significant increase in the holdings of other biological products, which rose by 3.43 percentage points [3][15]. Foreign Investment - Foreign investment in the pharmaceutical sector has shown a notable increase, with the total market value held by foreign investors rising to 1839.40 billion yuan [10][6]. - The report indicates that the foreign shareholding in the pharmaceutical sector is 2.41%, reflecting a slight decrease of 0.02 percentage points [10]. Top Holdings and Changes - The top five companies by total market value held by public funds are 药明康德 (461 billion yuan), 恒瑞医药 (427 billion yuan), 信达生物 (217 billion yuan), 迈瑞医疗 (199 billion yuan), and 康方生物 (135 billion yuan) [2][8]. - The report highlights significant increases in holdings for 药明康德 (+209.4 billion yuan) and 恒瑞医药 (+110.3 billion yuan) [2][8].

Investment Rating - The report maintains a positive outlook on the innovative drug sector and recommends focusing on companies with strong performance in medical devices, CXO, and upstream sectors [3][4]. Core Insights - The report highlights a 0.7% decline in the Shenwan Pharmaceutical Bio Index, while the Shanghai Composite Index rose by 0.4% during the same period [3][4]. - The new National Medical Insurance Drug List added 114 drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly up from 76% in 2024 [3][13]. - The launch of the Chinese Drug Price Registration System allows companies to self-declare innovative drug prices, enhancing the global pricing strategy for these drugs [19][21]. - Recent clinical trial successes and milestone payments indicate a robust pipeline for several companies, including a $250 million milestone payment received by BaiLi Tianheng [26][29]. Market Performance - The Shenwan Pharmaceutical Bio Index ranked 21st among 31 Shenwan first-level sub-industries, with a current overall valuation of 29.3 times earnings, placing it 10th among all first-level industries [3][4][6]. - Various sub-sectors showed mixed performance, with medical circulation and offline pharmacies seeing increases of 6.5% and 1.8%, respectively, while raw materials and chemical preparations declined by 2.5% and 0.9% [3][6]. Recent Key Events - The report notes the release of the first Commercial Health Insurance Innovative Drug Directory, which includes 19 drugs aimed at enhancing coverage for critical diseases and rare conditions [13][18]. - The FDA's drug review center director's resignation adds uncertainty to the regulatory environment, which may impact drug approvals and market dynamics [19][21]. - The report emphasizes the importance of monitoring flu vaccine stocks and related pharmaceutical companies as flu activity rises [22]. Company Dynamics - BaiLi Tianheng received a significant milestone payment, indicating strong progress in its global drug development efforts [26]. - Junsheng Pharmaceutical announced positive results from a head-to-head clinical trial, showcasing the advantages of its new drug HTD1801 over existing treatments [29]. - Heng Rui Pharmaceutical appointed a new senior vice president from Eli Lilly, enhancing its research and development capabilities [30]. - Kelong Botai entered a strategic partnership to develop and commercialize new cancer therapies, indicating a focus on innovative treatment options [31]. IPO Dynamics - Lingke Pharmaceutical has initiated its IPO process in Hong Kong, focusing on innovative small molecule drugs for autoimmune and inflammatory diseases [34]. - Hansi Aitai's IPO application has passed the hearing process, indicating strong market interest in its dual-function antibody therapies [36].

Investment Rating - The report maintains a "Buy" rating for certain stocks in the CXO sector, indicating a positive outlook for the industry [58]. Core Insights - The global market is showing signs of recovery, with domestic financing on the rise, particularly in the healthcare sector. In Q3 2025, global financing reached $20.6 billion, marking a 39% increase and the highest in nearly four years. Domestic financing also surged to 18.2 billion yuan, up 97% [2][21]. - The IPO landscape is experiencing a divergence, with overseas markets facing challenges while domestic IPOs are rebounding. The domestic biotech IPOs have seen significant growth, with a 665% year-on-year increase in fundraising [30][34]. - The research and development sector is under pressure globally, but domestic R&D is showing rapid improvement, with new clinical trials reaching historical highs. In the first eleven months of 2025, the number of new clinical trials in China increased by 20% [41][52]. Summary by Sections Financing Sector - Global financing in the healthcare sector is recovering, with Q3 2025 showing a significant rebound. The total financing for the first ten months of 2025 has already surpassed the entire year of 2024 [14][21]. - Domestic financing trends mirror global patterns, with a notable increase in Q3 2025, indicating a clear upward trajectory [21][22]. IPO Trends - The overseas IPO market is stabilizing after a downturn, while domestic IPOs are experiencing a resurgence, particularly in the biotech sector, driven by a favorable secondary market [30][34]. - The first eleven months of 2025 saw a dramatic increase in fundraising from domestic biotech IPOs, highlighting a strong recovery [34][36]. R&D Developments - Globally, the number of new clinical trials is declining, but the domestic market is witnessing a significant turnaround, with new drug IND applications showing stability and growth [41][47]. - The number of new clinical trials in China has reached a historical high, with a notable increase in Phase II trials, indicating a robust pipeline for future drug development [52][53].

Core Insights - The CSI Medical Index (399989) closed at 6861.88 points, up 0.97%, with a trading volume of 12.693 billion yuan and a turnover rate of 0.95% [1] - Among the index constituents, 41 stocks rose, with Furuide Co., Ltd. leading with a 7.09% increase, while 9 stocks fell, with Haier Biomedical leading the decline at 1.56% [1] Index Constituents - The top ten constituents of the CSI Medical Index include: - WuXi AppTec (13.57% weight, latest price 90.40 yuan, market cap 269.732 billion yuan) [1] - Mindray Medical (8.35% weight, latest price 202.39 yuan, market cap 245.386 billion yuan) [1] - United Imaging Healthcare (8.07% weight, latest price 130.61 yuan, market cap 107.643 billion yuan) [1] - Yeye Eye Hospital (6.58% weight, latest price 11.30 yuan, market cap 105.377 billion yuan) [1] - Tigermed (3.23% weight, latest price 49.45 yuan, market cap 42.578 billion yuan) [1] - Kanglong Chemical (3.15% weight, latest price 29.21 yuan, market cap 51.941 billion yuan) [1] - New Industry (2.84% weight, latest price 59.87 yuan, market cap 47.041 billion yuan) [1] - Jingmeike (2.70% weight, latest price 142.97 yuan, market cap 43.262 billion yuan) [1] - Jiao Yue Medical (2.63% weight, latest price 36.14 yuan, market cap 36.230 billion yuan) [1] - Lepu Medical (2.57% weight, latest price 15.83 yuan, market cap 29.181 billion yuan) [1] Capital Flow - On the day, the CSI Medical Index constituents experienced a net outflow of 127 million yuan from institutional investors and 219 million yuan from retail investors, while retail investors saw a net inflow of 346 million yuan [3] - Detailed capital flow for key stocks includes: - WuXi AppTec: net inflow of 214 million yuan from institutions, net outflow of 174 million yuan from retail [3] - Furuide Co., Ltd.: net inflow of 27.11 million yuan from institutions, net outflow of 23.27 million yuan from retail [3] - Meinian Health: net inflow of 26.73 million yuan from institutions, net outflow of 18.92 million yuan from retail [3] Index Adjustments - Recent adjustments to the CSI Medical Index included the addition of 6 stocks and the removal of 6 stocks [3] - Newly added stocks include: - Jinbo Biological (250 million yuan market cap) [4] - Haoyuan Pharmaceutical (16.122 billion yuan market cap) [4] - Rejing Biological (16.224 billion yuan market cap) [4] - Weigao Blood Purification (16.890 billion yuan market cap) [4] - Boteng Co., Ltd. (12.9347 billion yuan market cap) [4] - Dabo Medical (19.943 billion yuan market cap) [4] - Stocks removed include: - Yihua Biological (8.618 billion yuan market cap) [4] - Xinhua Medical (9.112 billion yuan market cap) [4] - Fulejia (14.412 billion yuan market cap) [4]